Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea
NCT03925441 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2
Last updated 2020-06-12
Summary
The objective of this study is to evaluate the real world safety and effectiveness of adalimumab (Humira) for the treatment of Korean patients with pediatric chronic severe plaque psoriasis under a routine treatment practice.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AbbVie Inc. · AbbVie
Eligibility
- Min Age
- 4 Years
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-06-25
- Primary Completion
- 2019-08-06
- Completion
- 2019-08-06
Countries
- South Korea
Study Locations
More Related Trials
-
Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)
NCT01076192 ·Status: COMPLETED
-
Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
NCT01202565 ·Status: COMPLETED
-
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
NCT02016105 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
NCT02581345 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645814 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00195676 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00646191 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06869551 ·Status: RECRUITING ·Phase: PHASE3
-
Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
NCT00735787 ·Status: COMPLETED ·Phase: PHASE4
-
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
NCT05073315 ·Status: COMPLETED ·Phase: PHASE3
-
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis
NCT01387815 ·Status: COMPLETED
-
To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT05495568 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
NCT04263610 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
NCT04453137 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
NCT01729754 ·Status: COMPLETED ·Phase: PHASE3
-
Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis
NCT01432249 ·Status: WITHDRAWN
-
A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis
NCT00513370 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
NCT01090427 ·Status: COMPLETED ·Phase: PHASE3
-
Post Marketing Observational Study on Venezuelan Patients With Psoriasis
NCT01758705 ·Status: WITHDRAWN
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453 ·Status: RECRUITING ·Phase: PHASE3
-
Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
NCT01316224 ·Status: COMPLETED
-
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00338754 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
NCT03236870 ·Status: COMPLETED
-
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
NCT01169987 ·Status: COMPLETED
-
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
NCT02982005 ·Status: COMPLETED ·Phase: PHASE3